Major companies have shifted their focus on R&D activities in the RFAD market, resulting in large number of product developments (approvals & launches), and in turn contributing to the market growth. Acquisition is the another key strategy adopted by larger companies to acquire smaller and emerging companies, owing to the presence of large number of small- to mid-sized companies in the radiofrequency ablation devices market.
Radiofrequency ablation (RFA) is a minimally invasive procedure, appropriate for patients with cardiac diseases (such as atrial fibrillation (AF), atrial flutter, cardiac arrhythmias), cancer and pain management. RFA is being increasingly used for the treatment of many diseases. such as cancer and cardiac arrhythmia.
Get the PDF of Radiofrequency Ablation Devices Industry Study at: https://tinyurl.com/yd4t9elt
Growth is favored by the increase in prevalence of cardiovascular diseases, such as, atrial fibrillation, incidence of patients’ suffering from cancer and pain, and increase in demand for minimally-invasive procedures. It includes revenue generated from the sales of ablation devices that use radiofrequency energy for the process of ablation. RFA is one of the most widely used methods in the electrophysiology market with a success rate of over 90%, as per clinical trials.
There are two types of ablation catheters viz. conventional and irrigated-tip RFA catheters that can be used for the cardiology segment. The pain management segment is further divided into neck, shoulder, upper back, lower back, knee pain, and other pain syndromes. The Venezuelan radiofrequency ablation devices industry is estimated to reach $3.3 million by 2022 growing at a CAGR of 11.4% over the next seven years. The key players profiled in this report include Halyard Health, Inc., Stryker Corporation, St. Jude Medical, Inc., Medtronic Plc, Boston Scientific Corporation, C. R. Bard, Inc., AngioDynamics, Inc., Hologic, Inc., AtriCure, Inc., and Johnson & Johnson.
The cardiology application segment dominated the RFAD market due to the well-established adoption of radiofrequency devices to treat cardiac arrhythmias. RFA is one of the most widely used methods in the electrophysiology market with a success rate of over 90%, as per clinical trials. In cardiology, irrigated RF ablation catheters are projected to grow at a CAGR of 11.6% due to their wide acceptability in the treatment of atrial fibrillation.
Oncology would be the fastest growing application market owing to the increasing preference for RFAD over chemotherapy (considering its side effects) and projected to grow at a CAGR of 14.2%. Breast cancer was the leading application for the oncology radiofrequency ablation devices market; whereas, kidney cancer would be the fastest growing segment. This is due to the fact that breast cancer is the second most common type of cancer and accounted for around one-fourth share of all cancer cases in 2015.
The key players profiled in this report include Halyard Health, Inc., Stryker Corporation, St. Jude Medical, Inc., Medtronic Plc, Boston Scientific Corporation, C. R. Bard, Inc., AngioDynamics, Inc., Hologic, Inc., AtriCure, Inc., and Johnson & Johnson. Other players in the RFAD market include Baylis Medical, Arthrex, Inc., inomed Medizintechnik GmbH, Sutter Medizintechnik GmbH, Bramsys Indstria e Comrcio Ltda, ENDO-FLEX GmbH, Epimed International, and sfm medical devices GmbH.
Do Purchase Inquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/421